Participation as a Service Provider in K-AI New Drug Development Project, Ensuring Data Security
Agentic AI Automation for Chongkundang, Driving Operational Innovation
LG CNS is expanding its artificial intelligence transformation (AX) business beyond the financial, manufacturing, public, and defense sectors into the pharmaceutical and bio industries. The company recently signed a contract for a government-led new drug development project and completed the establishment of an automated product quality evaluation system for Chongkundang.
Kim Taehoon, Vice President and Head of AI Cloud Business at LG CNS (4th from the right), and Jang Minyong, Senior Executive Director and Head of Chemical/Battery Business Division (3rd from the right), are taking a commemorative photo with representatives from Chongkundang. Provided by LG CNS
On January 21, LG CNS announced that it will participate as a service provider in the "K-AI New Drug Development Preclinical and Clinical Model Development Project (R&D)" promoted by the Ministry of Health and Welfare. This is a national research project with approximately 37.1 billion won in government funding over four years and three months.
In this project, LG CNS will lead the development of an "AI-based clinical trial design and support platform for new drug development." The company will also implement an integrated management system that links various AI models for new drug development, which are being developed by other participating institutions, using agentic AI to maximize synergy.
In particular, LG CNS will apply "federated learning" technology, enabling multiple institutions such as hospitals and clinical research centers to jointly train AI models securely without sharing data externally. This approach will allow safe use of highly sensitive medical data while connecting previously siloed preclinical and clinical stages, ultimately accelerating new drug development and increasing its success rate.
According to the industry, new drug development typically requires 10 to 15 years and enormous costs, with a failure rate of up to 90% in the clinical trial phase. The structurally fragmented nature of clinical trials between institutions and limited data utilization have long been cited as fundamental challenges in the field of new drug development.
LG CNS plans to increase the success rate of new drug development by leveraging its bio AI platform, which combines specialized capabilities in protein structure analysis and design for the pharmaceutical and bio industries with the latest AI technologies.
In addition, LG CNS has driven practical innovation at pharmaceutical sites. Recently, the company succeeded in automating Chongkundang's annual product quality review (APQR) report preparation process using agentic AI.
By utilizing LG CNS’s enterprise agentic AI platform, "AgenticWorks," approximately 30 AI agents autonomously collaborate to collect, analyze, validate data, and generate reports, establishing a multi-agent architecture.
With just a few clicks, all data from core systems such as the Quality Management System (QMS) and Laboratory Information Management System (LIMS) can be collected, analyzed, validated, and compiled into a report in one seamless process.
Domestic pharmaceutical and bio companies conduct regular annual quality evaluations based on various domestic regulations, recording the results in APQRs. Previously, preparing a report for each product required significant time, but since the introduction of the "Agentic AI-based APQR Automation Service" built by LG CNS, document generation time has been reduced by more than 90%. Chongkundang can now focus the saved time on final verification, maximizing report quality.
Kim Taehoon, Vice President and Head of AI Cloud Business at LG CNS, stated, "LG CNS's pharmaceutical and bio AX capabilities have been recognized by the government and pharmaceutical companies, resulting in tangible achievements. By leading in agentic AI technology, we will enhance the competitiveness of Korea’s pharmaceutical and bio industries and become a game changer that delivers differentiated customer value."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
